The Company’s policy is to assess goodwill and indefinite-lived intangible assets for impairment annually as of April 1, with more frequent assessments if events or changes in circumstances indicate the asset might be impaired. Impairment charges are recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations.

For the three months ended March 31, 2025, the Company considered qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in a more likely than not impairment of any of its goodwill or indefinite-lived intangible assets during the course of the quarter, and concluded there were no such indicators.

In the three months ended March 31, 2024, the Company identified indicators of a more likely than not impairment related to certain indefinite-lived imaging product trade names within the Connected Technology Solutions segment. The decline in fair value of these indefinite-lived trade names was driven by declines in volumes during the three months ended March 31, 2024, which was due in part to a loss in market share from competitive pricing pressures, as well as unfavorable economic conditions

in certain markets. These factors contributed to a reduction in forecasted revenues in the near term. The trade names were evaluated for impairment using an income approach, specifically a relief from royalty method. As a result, the Company recorded an indefinite-lived intangible asset impairment charge of $6 million for the three months ended March 31, 2024.


(in millions)	Connected Technology Solutions		Essential Dental Solutions		Orthodontic and Implant Solutions		Wellspect Healthcare		Total






















Balance at December 31, 2024
Goodwill	$	291	$	829	$	1,276	$	265	$	2,661
Accumulated impairment losses	(291)		—		(773)		—		(1,064)
Goodwill, net at December 31, 2024	—		829		503		265		1,597

Impairment	—		—		—		—		—
Foreign Currency Translation	—		10		19		6		35

Balance at March 31, 2025
Goodwill	$	291	$	839	$	1,295	$	271	$	2,696
Accumulated impairment losses	$	(291)	$	—	$	(773)	$	—	$	(1,064)
Goodwill, net at March 31, 2025	$	—	$	839	$	522	$	271	$	1,632


	March 31, 2025						December 31, 2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount

Developed technology and patents	$	1,688	$	(1,146)	$	542	$	1,639	$	(1,079)	$	560
Trade names and trademarks	80		(74)		6		79		(73)		6
Licensing agreements	43		(29)		14		29		(28)		1
Customer relationships	1,049		(755)		294		1,019		(716)		303
Total definite-lived	2,860		(2,004)		856		2,766		(1,896)		870

Indefinite-lived trade names and trademarks	351		—		351		332		—		332
In-process R&D	5		—		5		5		—		5
Total indefinite-lived	356		—		356		337		—		337

Total identifiable intangible assets	$	3,216	$	(2,004)	$	1,212	$	3,103	$	(1,896)	$	1,207

In the three months ended March 31, 2025, the Company acquired naming and certain other rights to a university dental laboratory in exchange for $14 million of equipment and consumable products to be transferred to the university through 2040. These rights were recorded as an intangible asset to be amortized over a fifteen-year period, with an offsetting contract liability that will be relieved as the products are provided to the university.